Cancer Advisor

GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes. As their use expands globally, a critical question is emerging: Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health? This article reviews: The established link between obesity and cancer The biological mechanisms affected by GLP-1 therapy Human clinical trial data Observational cancer incidence studies Safety signals (including thyroid cancer) What remains unknown All claims below are supported by peer-reviewed sources. 1. Obesity and Cancer: Established Evidence The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1). Key cancers linked to obesity include: Colorectal Postmenopausal breast Endometrial Pancreatic Liver Mechanisms supported by human and transl...

If you trying to understand and looking for evidence about time-restricted eating, you've come to the right place. Time-restricted eating is just what it sounds like. It's a form of intermittent fasting where you eat all of your meals for the day within a restricted window of time, ranging from two to eight hours. That means you're avoiding food (fasting) for 16 to 22 consecutive hours. Eating within a four- to six-hour window is likely close to metabolic ideal for most. As noted in the paper "A Time to Fast," published in the November 2018 issue of Science : "Adjustment of meal size and frequency have emerged as powerful tools to ameliorate and postpone the onset of disease and delay aging, whereas periods of fasting, with or without energy intake, can have profound health benefits. The underlying physiological processes involve periodic shifts of metabolic fuel sources, promotion of repair mechanisms, and the optimization of energy utilization for cellular ...